Skye Bioscience Inc.(US:SKYE) TMX Newsfile·2026-01-06 17:51Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025 [1][2]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Performance - Skye Bioscience's lead product candidate, nimacimab, reportedly did not meet the primary weight-loss endpoint in a Phase 2a study, leading to a significant drop in share price [4]. - Following the announcement of the study results, Skye's share price fell by 60%, decreasing from $4.75 to $1.90 per share [4]. Group 3: Company Background - Skye Bioscience is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2].